919 related articles for article (PubMed ID: 7636741)
1. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
[TBL] [Abstract][Full Text] [Related]
4. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
5. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Schott Y; Decker M; Rommelspacher H; Lehmann J
Bioorg Med Chem Lett; 2006 Nov; 16(22):5840-3. PubMed ID: 16945529
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of two different cholinesterases by tacrine.
Ahmed M; Rocha JB; Corrêa M; Mazzanti CM; Zanin RF; Morsch AL; Morsch VM; Schetinger MR
Chem Biol Interact; 2006 Aug; 162(2):165-71. PubMed ID: 16860785
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
8. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
9. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.
Boudinot E; Taysse L; Daulon S; Chatonnet A; Champagnat J; Foutz AS
Pharmacol Biochem Behav; 2005 Jan; 80(1):53-61. PubMed ID: 15652380
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
[TBL] [Abstract][Full Text] [Related]
11. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Mesulam MM; Geula C; Morán MA
Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Szymański P; Janik A; Zurek E; Mikiciuk-Olasik E
Pharmazie; 2011 Jun; 66(6):399-403. PubMed ID: 21699076
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
14. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity.
Hartmann J; Kiewert C; Duysen EG; Lockridge O; Greig NH; Klein J
J Neurochem; 2007 Mar; 100(5):1421-9. PubMed ID: 17212694
[TBL] [Abstract][Full Text] [Related]
15. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of huperzine B on cholinesterase activity in mice.
Liu J; Zhang HY; Wang LM; Tang XC
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):141-5. PubMed ID: 10437161
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
19. New tacrine-hydrazinonicotinamide hybrids as acetylcholinesterase inhibitors of potential interest for the early diagnostics of Alzheimer's disease.
Szymański P; Zurek E; Mikiciuk-Olasik E
Pharmazie; 2006 Apr; 61(4):269-73. PubMed ID: 16649535
[TBL] [Abstract][Full Text] [Related]
20. The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity.
Siwicka A; Moleda Z; Wojtasiewicz K; Zawadzka A; Maurin JK; Panasiewicz M; Pacuszka T; Czarnocki Z
J Pineal Res; 2008 Aug; 45(1):40-9. PubMed ID: 18284552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
